

Spina Bifida Guideline

Bowel function and care: Guidelines for the care of people with spina bifida

Patricia Beierwaltes^{a,*}, Paige Church^b, Tiffany Gordon^c and Lusine Ambartsumyan^d

^a*Minnesota State University Mankato, Mankato, MN, USA*

^b*The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada*

^c*Workforce Professional Development and Family Nurse Practitioner Clinical Experiences, Minnesota State University Mankato, Mankato, MN, USA*

^d*University of Washington, Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA, USA*

Abstract.

PURPOSE: Bowel dysfunction, such as constipation and fecal incontinence, has a significant impact on health, activities of daily living, and quality of life among people with spina bifida. Secondary complications may result from bowel dysfunction and include urologic dysfunction, loss of skin integrity, shunt (hydrocephalus) function, as well as loss of social opportunities and employability.

METHODS: Using a consensus building methodology, the guidelines for management of bowel dysfunction in spina bifida were written by experts in the field of spina bifida and bowel function and care.

RESULTS: The evidence-based guidelines are presented in table format and provide age-specific recommendations to achieve fecal continence without constipation. Recommended treatments are presented from least to most invasive options. Literature supporting the recommendations and the interval research published to date is also presented.

CONCLUSION: These guidelines present a standardized approach to management of bowel dysfunction in spina bifida. Bowel management in children and young adults with spina bifida is limited by variability in clinical practice and paucity of robust research in neurogenic bowel. Collaborative multi-institutional efforts are needed to overcome research barriers and provide innovative solutions.

Keywords: Spina bifida, neural tube defects, neurogenic bowel, neurogenic bowel dysfunction, constipation, fecal incontinence, bowel management

1. Introduction

Bowel dysfunction, such as constipation and fecal incontinence, have a significant impact on quality of life and well-being of individuals with spina bifida as well as their parents [1–5]. This was highlighted in 2019 when the Spina Bifida Association conducted a survey of adults with and parents of both children and

adults with spina bifida. When asked about the impact of bowel incontinence, 50% of parents of children rated it as their biggest issue. Parents of adults with spina bifida rated it as their 3rd most important issue, with 48% of them citing it as a “very big issue”. Adults with spina bifida ranked bowel incontinence as the 2nd most important issue with 47% citing it as a “very big issue”. These results highlight the importance of the guidelines for bowel function and care [6].

Managing bowel function can be one of the biggest challenges accompanying the diagnosis of spina bifida and is also one of the most important. In spina bifida,

*Corresponding author: Patricia Beierwaltes, Minnesota State University Mankato – Edina Hub, 7700 France Ave. S, Edina, MN, 55435, USA. Tel.: +1 13 610 8001; E-mail: Patricia.beierwaltes@mnsu.edu.

the secondary complications from neurogenic bowel dysfunction extend beyond constipation and fecal incontinence to include urinary incontinence, urinary tract infections, shunt (hydrocephalus) malfunction, potential for skin breakdown, hemorrhoids, anal fissures, loss of social and work opportunities, and decreased quality of life [3,5,7–10]. Proactive, systematic and rational approaches to these problems can lead to continence and a more functional lifestyle [7,11–17]. Thus, the guidelines were written to emphasize bowel management in spina bifida to address a specific goal: bowel continence without constipation.

In spina bifida, the lack of normal nerve function and subsequent loss of sensory and motor control significantly impact the lower gastrointestinal tract and colorectal function. Slow colonic transit, probable alterations in colorectal motility, abnormal anal sphincter function, and decreased sensation lead to constipation and fecal incontinence [15,16]. Attention to these pathophysiologic mechanisms of neurogenic bowel will lead to a better understanding, increased adherence to treatment, and increased probability of attaining the goal of continence without constipation. Treatment should be considered from least to most invasive and the guidelines are intended as a step by step guide to achieve continence without constipation.

The guidelines are designed to be adaptable to each individual. Tailoring the treatment to the individual's mobility, cognitive development, and underlying medical and social comorbidities is important in the success of the bowel program [7,11–13,16–19]. These guidelines should be followed with the guidance of a health-care professional who has expertise in bowel management in spina bifida.

1.1. Guidelines goals and outcomes

The goals and outcomes are based on what is healthy from a medical standpoint and also on what is desirable from a personal-social standpoint. As can be seen from the outcomes listed here, the bowel guidelines are both practical and aspirational in that the authors believe continence without constipation is possible for the majority of patients.

For the bowel care guidelines, the following outcomes were identified:

Primary Outcomes (intervene before health effect occurs)

- Maintenance of social continence as appropriate for age level

Secondary Outcomes (screen and identify problems in the earliest stages)

- Maximization of independence with managing bowel program
- Maximized knowledge and compliance with diet and bowel program

Tertiary Outcomes (try to improve quality of life and reduce the symptoms)

- Minimization of constipation

2. Methods

The methodology for writing the guidelines have been published by Dicianno et al. [20]. The process included one hundred Spina Bifida experts from around the world. The work includes 24 topics, including bowel function and care for people with spina bifida from birth through adulthood [21].

2.1. Clinical questions that informed the bowel function and care guidelines

A set of clinical questions was the foundation of the Bowel Management Guidelines. These clinical questions were used to focus attention on the outcomes or goals of the guidelines and inform the guidelines. Table 1 shows clinical questions specific to five sequential age groups. These questions informed the research and writing of the guidelines. There were five clinical questions that were pertinent to all of the age groups, which are listed here:

1. What is expected for bowel management at each stage of life (infancy, toddler, preschool, school age, teenage & adult)?
2. What are the options for bowel management at each stage of life?
3. What bowel symptoms should be evaluated by age?
4. Why is patient satisfaction important in regard to bowel management?
5. What education relating to bowel management is necessary for life long positive outcomes?

3. Results

The guidelines for management of bowel dysfunction in spina bifida are presented in Table 2. Each age group is represented with consideration given to the potential variations in their functional abilities. Literature supporting the guidelines of care and the interval research

Table 1
Clinical questions that informed the bowel function and care guidelines

Age group (from guidelines)	Clinical questions
0–11 months	– What evidence exists that prevention of constipation in the first year of life improves outcome of bowel management in later childhood?
1–2 years 11 months	– Is there evidence to support the benefit of toilet training a child with Spina Bifida at the same developmental stage as peers without dysfunction?
3–5 years 11 months	– Is there evidence that “habit training,” or forced evacuation with stimulants, such as suppositories or enemas, increases social continence?
6–12 years 11 months	– What is the evidence that the MACE (Malone antegrade continence enema) procedure or continent cecostomy is an effective form of bowel management in children with refractory incontinence? – What are the most effective protocols for MACE (ACE) management? – What is the evidence that electrical stimulation (sacral nerve or intravesicular) provides benefit for increased bowel continence?
13–17 years 11 months	– What support is needed by young adults with Spina Bifida to be successful in maintaining their bowel program? – Is there evidence that hormonal fluctuations impact continence?
18+ years	– What impact does pregnancy have on bowel management or on use of a cecostomy or MACE? (Women’s Health Guidelines) – Does early chronic constipation impact management of constipation in adult years? – Is there a change in bowel function later in life that should be addressed with a more aggressive bowel program? Does menopause result in changes?

Table 2
The guidelines for bowel care and function for people with spina bifida and the citations of supporting evidence

Age group	Guidelines	Evidence
0–11 months	1. Monitor stool frequency, consistency, and amounts.	[7, 8, 11]
	2. Monitor stool frequency, consistency, and amounts.	[8, 11–14, 16, 18]
	3. Use dietary management, in particular breastfeeding if possible, as breastmilk is easier to digest and offers better restoration of the microbiome after surgery.	[8, 11–14, 16, 18]
	4. Consider dietary management (fiber and fluids) before pharmacologic adjuncts (sennoside), and/or rectal stimulants (glycerin suppositories) to manage constipation.	[8, 11–14, 16, 18, 23], clinical consensus
	5. Use barrier creams to protect perineal area from breakdown as needed.	[11, 17, 24], Integument (Skin) Guidelines
1–2 years 11 months	1. Discuss toilet training and habit training with parents.	[8, 10–11, 17–18]
	2. Establish goal of working toward bowel continence.	[8, 10–11, 17–18]
	3. Focus on fiber, fluids, exercise, and timed bowel movements after meals.	[8, 11, 14–15, 18–19]
	4. Consider two-pronged approach of oral and rectal interventions to meet the goal of bowel continence without constipation.	[8, 11, 14–15, 18–19]
	5. Use dietary management (fiber and fluids), pharmacologic adjuncts (sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to manage constipation and fecal incontinence.	[8, 11, 14–15, 18–19]
	6. Use barrier creams to protect perineal area from breakdown as needed.	[11, 17, 24] Integument (Skin) Guidelines
3–5 years 11 months	7. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida.	[8, 10], clinical consensus
	1. Discuss consequences of constipation and bowel incontinence (including shunt malfunction, urinary tract infections (UTIs), skin breakdown, social isolation).	[3–5, 7, 10, 18]
	2. Establish the goal of bowel continence and institute the bowel continence program using guidelines below.	[3–5, 7, 10, 18]
	3. Focus on fiber, fluids, exercise, and timed bowel movements after meals.	[8, 11, 14–15, 18–19]
	4. Consider two-pronged approach of oral and rectal interventions to meet the goal of bowel continence without constipation.	[8, 11, 14–15, 18–19]
	5. Use dietary management (fiber and fluids), pharmacologic adjuncts (sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to manage constipation and fecal incontinence.	[8, 11, 14–15, 18–19]
	6. Use barrier creams to protect perineal area from breakdown as needed.	[11, 17, 24] Integument (Skin) Guidelines
7. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida.	[8, 10], clinical consensus	

Table 2, continued

Age group	Guidelines	Evidence
6–12 years, 11 months	1. Discuss consequences of constipation and bowel incontinence (including shunt malfunction, urinary incontinence, UTIs, skin breakdown, social isolation) and focus on developing independent management skills.	[3–5, 7, 10, 18, 23], Self-Management and Independence Guidelines
	2. Establish the goal of bowel continence and institute the bowel continence program using guidelines below.	[3–5, 7, 10, 18]
	3. Assist the child with learning how to minimize and manage bowel accidents.	[7, 11, 24, 26]
	4. Use barrier creams to protect perineal area from breakdown as needed.	[11, 17, 24] Integument (Skin) Guidelines
	5. Keep a bowel habit diary to better understand triggers for incontinence and overall patterning to direct a choice of options for bowel management.	[10–12, 17, 18]
	6. Focus on fiber, fluids, exercise, and timed bowel movements after meals.	[8, 11, 14–15, 18–19]
	7. Consider twofold attack of oral and rectal interventions to meet the goal of bowel continence without constipation or fecal incontinence.	[8, 11, 14–15, 18–19]
	8. Use dietary management (fiber, fiber supplements, and fluids), pharmacologic adjuncts (sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to manage constipation.	[8, 11, 14–15, 18–19]
	9. Discuss other options for treatment if the above have failed, including cone enema or other transanal irrigation, cecostomy, or MACE.	[8, 11, 14–15, 18–19, 25–28]
	10. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida.	[8, 10, 11, 19], clinical consensus
13–17 years, 11 months	1. Discuss consequences of constipation and bowel incontinence (including shunt malfunction, urinary incontinence, UTIs, skin breakdown, social isolation) and focus on developing independent management skills.	[3–5, 7, 10, 18, 23], Self-Management and Independence Guidelines
	2. Establish the goal of bowel continence and institute the bowel continence program using guidelines below.	[3–5, 7, 10, 18]
	3. Assist the child with learning how to minimize and manage bowel accidents.	[7, 11, 24, 26]
	4. Use barrier creams to protect perineal area from breakdown as needed.	[11, 17, 24] Integument (Skin) Guidelines
	5. Keep a bowel habit diary to better understand triggers for incontinence and overall patterning to direct a choice of options for bowel management.	[10–12, 17, 18]
	6. Focus on fiber, fluids, exercise, and timed bowel movements after meals.	[8, 11, 14–15, 18–19]
	7. Consider twofold attack of oral and rectal interventions to meet the goal of bowel continence without constipation or fecal incontinence.	[8, 11, 14–15, 18–19]
	8. Use dietary management (fiber, fiber supplements, and fluids), pharmacologic adjuncts (sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to manage constipation.	[8, 11, 14–15, 18–19]
	9. Discuss other options for treatment if the above have failed, including cone enema or other transanal irrigation, cecostomy, or MACE.	[8, 11, 14–15, 18–19, 25–28]
	10. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida.	[8, 10, 11, 19], clinical consensus
18+ years	11. Access support services for personal care, if needed.	[11–12, 19, 24]
	1. Discuss consequences of constipation and bowel incontinence (including shunt malfunction, urinary incontinence, UTIs, skin breakdown, social isolation) and focus on developing independent management skills.	[3–5, 7, 10, 18, 23], Self-Management and Independence Guidelines
	2. Establish the goal of bowel continence and institute the bowel continence program using guidelines below.	[3–5, 7, 10, 18]
	3. Assist the child with learning how to minimize and manage bowel accidents.	[7, 11, 24, 26]
	4. Use barrier creams to protect perineal area from breakdown as needed.	[11, 17, 24] Integument (Skin) Guidelines
	5. Keep a bowel habit diary to better understand triggers for incontinence and overall patterning to direct a choice of options for bowel management.	[10–12, 17, 18]
	6. Focus on fiber, fluids, exercise, and timed bowel movements after meals.	[8, 11, 14–15, 18–19]
	7. Consider twofold attack of oral and rectal interventions to meet the goal of bowel continence without constipation or fecal incontinence.	[8, 11, 14–15, 18–19]
	8. Use dietary management (fiber, fiber supplements, and fluids), pharmacologic adjuncts (sennoside, polyethylene glycol), and/or rectal stimulants (glycerin, docusate sodium, or bisacodyl suppositories) to manage constipation.	[8, 11, 14–15, 18–19]
	9. Discuss other options for treatment if the above have failed, including cone enema or other transanal irrigation, cecostomy, or MACE.	[8, 11, 14–15, 18–19, 25–28]
	10. Refer to a Spina Bifida clinic or specialist with expertise in bowel management in Spina Bifida.	[8, 10, 11, 19], clinical consensus
11. Access support services for personal care, if needed.	[11–12, 19, 24]	




Fig. 1. Bowel management steps from conservative to higher levels of intervention are pictured here [19].

published to date is also presented accordingly. Treatment is presented in a stepwise manner from the least to most invasive options to achieve fecal continence without constipation as shown in Fig. 1 [19]. The guidelines should be individualized to meet the medical, developmental, and social needs of the child and young adult with spina bifida [11,19,22].

4. Discussion

Bowel dysfunction in children and young adults with spina bifida has a significant impact on their quality of life and social, emotional, and physical well-being [1]. Guidelines for bowel function and care of neurogenic bowel in spina bifida were developed to provide age-specific recommendations in order to achieve fecal continence without constipation [20]. The bowel program should be individualized to accommodate for the physical, developmental, medical, and social barriers. Ultimately, the desired outcomes are social continence in conjunction with education and compliance to foster independence [21].

The evaluation and management of bowel dysfunction in children and young adults with spina bifida is hampered by variability of practice within and between centers. This variability stems from limited robust clinical, translational, and basic science research in neurogenic bowel in children with spina bifida. Specifically, there is lack of normative physiologic data of colorectal function in neurogenic bowel. We must foster collaborations between the disciplines of clinical, basic, and translational research to better understand the pathophysiological mechanisms that underlie the aberrations in colorectal transit, motility, and sensation that result in fecal incontinence.

To accurately assess symptoms of neurogenic bowel and the impact of treatment interventions, we need reliable and validated questionnaires for children and caretakers. Two such promising questionnaires include the pediatric Neurogenic Bowel Dysfunction Score [29] and Adolescent Fecal Incontinence Constipation Symptom Index [30]. However, multi-institutional collaborative efforts are needed to design and execute larger validation studies. Additionally, initiative should be taken to standardize the use of validated questionnaires across institutions in future clinical trials.

In conjunction to these guidelines, social and community support as well as resources are recommended in order to provide all-inclusive care for children with spina bifida who suffer from bowel dysfunction. Resources, such as at-home bowel tracking, have been shown to be effective in revealing specific triggers that hamper the bowel program [11]. Standardized bowel tracking systems via paper and more importantly via smart phone application programs may be helpful to closely monitor and to implement in-time changes to bowel management. For school aged children, tracking of bowel movements and continence could be facilitated by school aids and teachers. The school nurse plays a vital role in assisting the child to reach educational goals and manage health concerns [12]. Development of educational resources for caretakers and teachers would be a great asset to the current and future guidelines of care.

4.1. Limitations

Clinical trials evaluating the efficacy of bowel regimens in children with spina bifida are hindered by variability in clinical practice and specifically non-standardized definitions of bowel success. Protocols utilizing algorithmic approaches to bowel management in children with spina bifida have been shown to be ef-

fective in ensuring fecal continence; however larger validation studies are needed [11]. Collaboration is needed between institutions to design large scale randomized controlled intervention studies with robust methodology to overcome these barriers. This would then allow us to evaluate the efficacy of different bowel regimens and design standardized treatment protocols based on clinical and diagnostic predictors of bowel success. Ultimately, we need to bridge the knowledge gap between clinical practice, research, and technology in order to develop innovative predictive modeling of bowel success in the neurogenic bowel of children with spina bifida.

In summary, bowel management in children and young adults with spina bifida is challenging and has significant psychosocial implications for the patient and caretakers alike. These guidelines provide a proactive, systematic, and rational approach to management of bowel dysfunction including fecal incontinence and constipation. Collaborative multi-institutional efforts are needed to overcome the research barriers and provide innovative solutions.

Acknowledgments

This edition of the *Journal of Pediatric Rehabilitation Medicine* includes manuscripts based on the most recent “Guidelines For the Care of People with Spina Bifida,” developed by the Spina Bifida Association. Thank you to the Spina Bifida Association for allowing the guidelines to be published in this forum and making them Open Access.

The Spina Bifida Association has already embarked on a systematic process for reviewing and updating the guidelines. Future guidelines updates will be made available as they are completed.

Executive Committee

- Timothy J. Brei, MD, Spina Bifida Association Medical Director; Developmental Pediatrician, Professor, Seattle Children’s Hospital
- Sara Struwe, MPA, Spina Bifida Association President & Chief Executive Officer
- Patricia Beierwaltes, DNP, CPNP, Guideline Steering Committee Co-Chair; Associate Professor, Nursing, Minnesota State University, Mankato
- Brad E. Dicianno, MD, Guideline Steering Committee Co-Chair; Associate Medical Director and Chair of Spina Bifida Association’s Professional Advisory Council; Associate Professor, Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine

- Nienke Dosa MD, MPH, Guideline Steering Committee Co-Chair; Upstate Foundation Professor of Child Health Policy; SUNY Upstate Medical University
- Lisa Raman, RN, MScANP, MEd, former Spina Bifida Association Director, Patient and Clinical Services
- Jerome B. Chelliah, MD, MPH, Johns Hopkins Bloomberg School of Public Health
- Julie Bolen, PhD, MPH, Lead Health Scientist, Rare Disorders Health Outcomes Team, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention
- Adrienne Herron, PhD Behavioral Scientist, Intervention Research Team, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
- Judy Thibadeau, RN, MN, Spina Bifida Association Director, Research and Services; former Health Scientist, National Spina Bifida Program, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention

Funding

The development of these Guidelines was supported in part by Cooperative Agreement UO1DD001077, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

Conflict of interest

Dr. Beierwaltes has been on the Coloplast Advisory Board for bowel management. The other authors have no conflicts of interest to report.

References

- [1] Sawin KJ, Bellin MH. Quality of life in individuals with spina bifida: a research update. *Dev Disabil Res Rev*. 2010; 16(1): 47–59. doi: 10.1002/ddrr.96.
- [2] Bakaniene I, Prasauskiene A, Vaiciene-Magistris N. Health-related quality of life in children with myelomeningocele: a systematic review of the literature. *Child Care Health Dev*. 2016 Sep; 42(5): 625–43. doi: 10.1111/cch.12367.
- [3] Choi EK, Im YJ, Han SW. Bowel management and quality of life in children with spina bifida in South Korea. *Gastroenterol Nurs*. 2017 May 1; 40(3): 208–15. doi: 10.1097/SGA.000000000000135.

- [4] Rocque BG, Ralee' Bishop E, Scogin MA, Hopson BD, Arynchyna AA, Boddiford CJ, et al. Assessing health-related quality of life in children with spina bifida. *J Neurosurg Pediatr*. 2015 Feb 1; 15(2): 144–9. doi: 10.3171/2014.10.PEDS1441.
- [5] Burns AS, St-Germain D, Connolly M, Delparte JJ, Guindon A, Hitzig SL, et al. Phenomenological study of neurogenic bowel from the perspective of individuals living with spinal cord injury. *Arch Phys Med Rehabil*. 2015 Jan 1; 96(1): 49–55. doi: 10.1016/j.apmr.2014.07.417.
- [6] Struwe S, Widener-Burrows D. Spina bifida gaps explored: A quantitative survey among adults with spina bifida and parents of children with spina bifida presented at Spina Bifida Clinical Care Meeting; 2019 Jun 29; Chicago.
- [7] Johnsen V, Skattebu E, Aamot-Andersen A, Thyberg M. Problematic aspects of faecal incontinence according to the experience of adults with spina bifida. *J Rehabil Med*. 2009 Jun 5; 41(7): 506–11. doi: 10.2340/16501977-0373.
- [8] McClurg D, Norton C. What is the best way to manage neurogenic bowel dysfunction? *BMJ*. 2016 Jul 27; 354: i3931. doi: 10.1136/bmj.i3931.
- [9] Ojetti V, Bruno G, Paolucci V, Triarico S, D'aversa F, Ausili E, et al. The prevalence of small intestinal bacterial overgrowth and methane production in patients with myelomeningocele and constipation. *Spinal Cord*. 2014 Jan; 52(1): 61–4. doi: 10.1038/sc.2013.131.
- [10] Wide P, Glad Mattsson G, Drott P, Mattsson S. Independence does not come with the method-treatment of neurogenic bowel dysfunction in children with myelomeningocele. *Acta Paediatr*. 2014 Nov; 103(11): 1159–64. doi: 10.1111/apa.12756.
- [11] Beierwaltes PS, Chinarian JL, Muñoz S, Suson KD. Using a decision tree to guide bowel management in spina bifida. *J Pediatr Nurs*. 2019 Jul 1; 47: 68–72. doi: 10.1016/j.pedn.2019.04.002.
- [12] Garman K, Ficca M. Managing encopresis in the elementary school setting: the school nurse's role. *J Sch Nurs*. 2012 Jun; 28(3): 175–80. doi: 10.1177/1059840511429685.
- [13] Coggrave M, Ash D, Adcock C, Brown A, Davies D, Dehal-Clark A, et al. Guidelines for management of neurogenic bowel dysfunction in individuals with central neurological conditions. Initiated by the Multidisciplinary Association of Spinal Cord. 2012: 1–60. Available from: <https://www.mascip.co.uk/wp-content/uploads/2015/02/CV653N-Neurogenic-Guidelines-Sept-2012.pdf>.
- [14] Kranz S, Brauchla M, Slavin JL, Miller KB. What do we know about dietary fiber intake in children and health? The effects of fiber intake on constipation, obesity, and diabetes in children. *Adv Nutr*. 2012 Jan; 3(1): 47–53. doi: 10.3945/an.111.001362.
- [15] Krassioukov A, Eng JJ, Claxton G, Sakakibara BM, Shum S. Neurogenic bowel management after spinal cord injury: a systematic review of the evidence. *Spinal Cord*. 2010 Oct; 48(10): 718–33. doi: 10.1038/sc.2010.14.
- [16] Lemelle JL, Guillemin F, Aubert D, Guys JM, Lottmann H, Lortat-jacob S, et al. A multicentre study of the management of disorders of defecation in patients with spina bifida. *Neurogastroenterol Motil*. 2006 Feb; 18(2): 123–8. doi: 10.1111/j.1365-2982.2005.00737.x.
- [17] Doolin E. Bowel management for patients with myelodysplasia. *Surg Clin North Am*. 2006 Apr 1; 86(2): 505–14. doi: 10.1016/j.suc.2005.12.009.
- [18] Velde SV, Biervliet SV, Bruyne RD, Winckel MV. A systematic review on bowel management and the success rate of the various treatment modalities in spina bifida patients. *Spinal Cord*. 2013 Dec; 51(12): 873–81. doi: 10.1038/sc.2013.123.
- [19] Ambartsumyan L, Rodriguez L. Bowel management in children with spina bifida. *J Pediatr Rehabil Med*. 2018 Jan 1; 11(4): 293–301. doi: 10.3233/PRM-170533.
- [20] Dicianno BE, Beierwaltes P, Dosa N, Raman L, Chelliah J, Struwe S, et al. Scientific methodology of the development of the guidelines for the care of people with spina bifida: an initiative of the spina bifida association. *Disabil Health J*. 2020 Apr 1; 13(2): 100816. doi: 10.1016/j.dhjo.2019.06.005.
- [21] Spina Bifida Association. 2018 Oct 25. Guidelines for the care of people with spina bifida. Available from: <https://www.spina-bifidaassociation.org/guidelines/>.
- [22] Kelly MS. Malone antegrade continence enemas vs. cecostomy vs. transanal irrigation – what is new and how do we counsel our patients? *Curr Urol Rep*. 2019 Aug 1; 20(8): 41. doi: 10.1007/s11934-019-0909-1.
- [23] Victora CG, Bahl R, Barros AJ, França GV, Horton S, Krausevec J, et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet*. 2016 Jan 30; 387(10017): 475–90. doi: 10.1016/S0140-6736(15)01024-7.
- [24] Baharestani MM, Ratliff CR. Pressure ulcers in neonates and children: an NPUAP white paper. *Adv Skin Wound Care*. 2007 Apr 1; 20(4): 208–20. doi: 10.1097/01.ASW.0000266646.43159.99.
- [25] Pardee C, Bricker D, Rundquist J, MacRae C, Tebben C. Characteristics of neurogenic bowel in spinal cord injury and perceived quality of life. *Rehabil Nurs*. 2012 May; 37(3): 128–35. doi: 10.1002/RNJ.00024.
- [26] Gordon T, Vandersteen DR, Dryjanski L, Carpenter J. Efficacy of Peristeen® transanal irrigation system for neurogenic bowel in the pediatric population. *J Pediatr Urol*. 2019 Dec 1; 15(6): 645–e1. doi: 10.1016/j.jpuro.2019.09.023.
- [27] Kelly MS, Dorgalli C, McLorie G, Khoury AE. Prospective evaluation of Peristeen® transanal irrigation system with the validated neurogenic bowel dysfunction score sheet in the pediatric population. *Neurourol Urodyn*. 2017 Mar; 36(3): 632–5. doi: 10.1002/nau.22979.
- [28] Sanders C, Bray L, Driver C, Harris V. Parents of children with neurogenic bowel dysfunction: their experiences of using transanal irrigation with their child. *Child Care Health Dev*. 2014 Nov; 40(6): 863–9. doi: 10.1111/cch.12117.
- [29] Kelly MS, Hannan M, Cassidy B, Hidas G, Selby B, Khoury AE, et al. Development, reliability and validation of a neurogenic bowel dysfunction score in pediatric patients with spina bifida. *Neurourol Urodyn*. 2016; 35(2): 212–7. doi: 10.1002/nau.22694.
- [30] Hubert K, Sideridis G, Sherlock R, Queally J, Rosoklija I, Kringle G, et al. Validation of a bowel dysfunction instrument for adolescents with spina bifida. *J Pediatr Urol*. 2015; 11(4): 199 e1–7. doi: 10.1016/j.jpuro.2015.06.001.



Enemeez® & Enemeez® Plus mini-enemas contain a delivered dose of 283 mg of docusate sodium

a solution proven effective for bowel care needs associated with spina bifida, spinal cord injury, traumatic brain injury, stroke, multiple sclerosis and general constipation in patients 12 years and older. A different formulation is available for children 2 to 12 years of age.



Actual Size



Bowel continence significantly affects quality of life for individuals with spina bifida. Enemeez (docusate sodium) provides a fast, effective and safe bowel management program, reducing time spent on bowel care.

Neurogenic Bowel, Constipation & Fecal Incontinence in Spina Bifida Patients

The hallmark clinical presentation is the inability to “voluntarily” control the defecation process or the inability to routinely perform elimination of stool/waste from the body. Patients with Spina Bifida may also experience:

- Constipation, very often severe
- Bowel obstructions, rectal impaction with sensory loss
- Hemorrhoids
- Nausea and vomiting
- Abdominal pain, bloating-distention, cramping, and lethargy – “sluggish feeling”
- Diet changes = decreased appetite - “grazing-snacking”
- Dehydration = electrolyte disturbances and increased UTI risk
- Soiling and unplanned evacuation of stool / social anxiety

Enemeez® & Enemeez® Plus Mini-Enemas are a Fast, Effective & Safe Solution

- ✓ Fast, predictable results typically in 2-15 minutes.¹
- ✓ Can assist in reducing time spent with patient for dressing/redressing due to episodes of incontinence or fecal discharge.²
- ✓ Can virtually eliminate episodes of incontinence.³
- ✓ No mucosal discharge⁴; helps to maintain healthy skin integrity
- ✓ Non-irritating formula. No after-burn.
- ✓ Easy rectal usage for patients with reflux issues or nausea.
- ✓ Enemeez® Plus includes 20mg of benzocaine, assisting in the anesthetization of the rectum & lower bowel. The formulation was developed for patients who experience painful bowel movement.

Request Samples for Your Facility Today

alliancelabsprovider.com/enemeez